acyl-CoA dehydrogenase medium chain
Last updated 3 Apr 2025
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The ACADM gene provides instructions for making an enzyme called medium-chain acyl-CoA dehydrogenase (MCAD). This enzyme functions within mitochondria, the energy-producing centers in cells. MCAD is essential for fatty acid oxidation, which is the multistep process that breaks down (metabolizes) fats and converts them to energy.
Video picks for GenesVideo library
Normal function
The ACADM gene provides instructions for making an enzyme called medium-chain acyl-CoA dehydrogenase (MCAD). This enzyme functions within mitochondria, the energy-producing centers in cells. MCAD is essential for fatty acid oxidation, which is the multistep process that breaks down (metabolizes) fats and converts them to energy.
MCAD is required to metabolize a group of fats called medium-chain fatty acids. These fatty acids are found in foods and body fat and are produced when larger fatty acids are metabolized. Fatty acids are a major source of energy for the heart and muscles. During periods without food (fasting), fatty acids are also an important energy source for the liver and other tissues.
Conditions referring to this gene or chromosome
Other names
ACAD1
ACADM_HUMAN
acyl-CoA dehydrogenase, C-4 to C-12 straight chain
MCAD
MCADH
Patient picks for Genes

Heart health and blood vessels
Coarctation of the aorta
Coarctation of the aorta is a type of congenital heart disease where there is a narrowing in part of the aorta, the main artery that leaves the left side of the heart.
by Dr Toni Hazell, FRCGP
Full body strength & conditioning exercises
Russian Kettlebell Swing
Improve hip power and glute strength with the Russian Kettlebell Swing. This exercise combines a hip hinge and swing motion, engaging your posterior chain muscles.

Workplace & corporate wellbeing
Developing Coaching Skills
Duration: 6:40.
by Stephen Brown

Workplace & corporate wellbeing
The difference between managing and coaching
Duration: 5:36.
by Stephen Brown
Related patient information and medicines

Patient information leaflet
Newborn bloodspot test
Medium-chain acyl-Co-A dehydrogenase deficiency (MCADD)- this is a very rare, but potentially life-threatening, inherited disorder, where fat cannot be broken down by the body as well as usual. Babies with this condition develop normally, but recognising the condition early enables parents to make sure their babies and children with t... When.

Patient information leaflet
Testicular cancer
Testicular cancer is a cancer that arises from a testicle (testis). Around half of all cases occur in men aged under 35 but testicular cancer rarely occurs before puberty. It is the most common cancer in men aged 15-44 years. There are about 2,000 new cases in the UK each year. The common early symptom of testicular cancer is a painless lump that.

Patient information leaflet
Allergies
Allergies are the body's response to a substance called an allergen. These may be harmless substances for the majority of people, but for some, the person's immune system reacts to the allergen, causing an allergic reaction. There are many possible allergens and many different allergic reactions can occur. What causes allergies. An allergy is a.

Patient information leaflet
Antihistamines
In the care of the terminally i... In the emergency treatment of severe allergic reactions. PatientPicksPlaceholder Antihistamine types Generally, antihistamines have been classified into two groups: First-generation or sedating antihistamines These can cause significant drowsiness and are generally more associated with the antimuscarinic.

Patient information leaflet
Gout
What is gout? | Patient Explainers Gout causes attacks of pain and swelling in one or more joints. Find out more: [https://patient.info/health/gout-leaflet](https://patient.info/health/gout-leaflet) Follow Patient: Website: [https://patient.info/](https://patient.info/) Facebook: [https://www.facebook.com/patient](https://www.facebook.com/patient).

Patient information leaflet
Jaundice
Jaundice treatment and outlook (prognosis) depends on the cause. What is jaundice. Liver function Liver function Jaundice is due to a build-up of a chemical called bilirubin in the tissues of the body. Bilirubin is a normal body chemical but can build up to abnormally high levels in various diseases. Jaundice: yellowish pigmentation of the sclera.
Further reading and references
- acyl-CoA dehydrogenase medium chain; MedlinePlus, National Library of Medicine.
- Gregersen N, Andresen BS, Corydon MJ, Corydon TJ, Olsen RK, Bolund L, Bross P. Mutation analysis in mitochondrial fatty acid oxidation defects: Exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship. Hum Mutat. 2001 Sep;18(3):169-89. doi: 10.1002/humu.1174.
- Hsu HW, Zytkovicz TH, Comeau AM, Strauss AW, Marsden D, Shih VE, Grady GF, Eaton RB. Spectrum of medium-chain acyl-CoA dehydrogenase deficiency detected by newborn screening. Pediatrics. 2008 May;121(5):e1108-14. doi: 10.1542/peds.2007-1993.
- Maier EM, Gersting SW, Kemter KF, Jank JM, Reindl M, Messing DD, Truger MS, Sommerhoff CP, Muntau AC. Protein misfolding is the molecular mechanism underlying MCADD identified in newborn screening. Hum Mol Genet. 2009 May 1;18(9):1612-23. doi: 10.1093/hmg/ddp079. Epub 2009 Feb 18.
- Maier EM, Liebl B, Roschinger W, Nennstiel-Ratzel U, Fingerhut R, Olgemoller B, Busch U, Krone N, v Kries R, Roscher AA. Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency. Hum Mutat. 2005 May;25(5):443-52. doi: 10.1002/humu.20163.
- Waddell L, Wiley V, Carpenter K, Bennetts B, Angel L, Andresen BS, Wilcken B. Medium-chain acyl-CoA dehydrogenase deficiency: genotype-biochemical phenotype correlations. Mol Genet Metab. 2006 Jan;87(1):32-9. doi: 10.1016/j.ymgme.2005.09.020. Epub 2005 Nov 15.
- Wang SS, Fernhoff PM, Hannon WH, Khoury MJ. Medium chain acyl-CoA dehydrogenase deficiency human genome epidemiology review. Genet Med. 1999 Nov-Dec;1(7):332-9. doi: 10.1097/00125817-199911000-00004.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

